Trials
Search / Trial NCT05660538

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

Launched by VERTEX PHARMACEUTICALS INCORPORATED · Dec 13, 2022

Trial Information

Current as of February 05, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Key Inclusion Criteria:
  • Diagnosis of diabetes mellitus type 1 or type 2 with
  • Glycosylated hemoglobin A1c (HbA1c) ≤9%; and
  • Presence of bilateral pain in lower extremities due to DPN for at least 1 year
  • Key Exclusion Criteria:
  • Painful neuropathy other than DPN
  • History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
  • History of a clinical atherosclerotic event, such as myocardial infarction or stroke, within the past 12 months
  • Other protocol defined Inclusion/Exclusion criteria may apply.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a global biotechnology company dedicated to the innovation and development of transformative therapies for serious diseases, particularly those with significant unmet medical needs. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex specializes in the research and commercialization of treatments for cystic fibrosis and other genetic disorders. Leveraging cutting-edge science and a commitment to patient-centric solutions, Vertex collaborates with healthcare professionals and researchers to advance clinical trials and bring groundbreaking therapies to market, aiming to improve the lives of patients worldwide.

Locations

Winston Salem, North Carolina, United States

Salt Lake City, Utah, United States

Anniston, Alabama, United States

Fleming Island, Florida, United States

Jacksonville, Florida, United States

Tustin, California, United States

Greensboro, North Carolina, United States

Berlin, New Jersey, United States

Hazelwood, Missouri, United States

Baytown, Texas, United States

Monroe, Louisiana, United States

Long Beach, California, United States

Maitland, Florida, United States

Cleveland, Ohio, United States

Fayetteville, North Carolina, United States

Cincinnati, Ohio, United States

Colorado Springs, Colorado, United States

Medford, Oregon, United States

Banning, California, United States

Flossmoor, Illinois, United States

Dearborn, Michigan, United States

Orangeburg, South Carolina, United States

East Greenwich, Rhode Island, United States

Decatur, Georgia, United States

El Dorado, Kansas, United States

Newton, Kansas, United States

North Dartmouth, Massachusetts, United States

Fort Myers, Florida, United States

Saint Peters, Missouri, United States

San Antonio, Texas, United States

Hallandale Beach, Florida, United States

Meridian, Idaho, United States

Wichita, Kansas, United States

Birmingham, Alabama, United States

Largo, Florida, United States

Miami, Florida, United States

Kansas City, Missouri, United States

Saint Louis, Missouri, United States

Charleston, South Carolina, United States

Dallas, Texas, United States

Henderson, Nevada, United States

New York, New York, United States

Bellevue, Washington, United States

Phoenix, Arizona, United States

Evansville, Indiana, United States

Anderson, South Carolina, United States

The Villages, Florida, United States

Waltham, Massachusetts, United States

Orlando, Florida, United States

Boston, Massachusetts, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials